Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from USFDA for Mesalamine Extended-Release Capsules13-08-2021
13-08-2021
CADILA HEALTHCARE LTD. - 532321 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Cadila Healthcare Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here12-08-2021
Cadila sees Q1 earnings driven by strong domestic performance
Cadila has entered into a supply and commercialization agreement with TLC, to market Liposomal Amphotericin B, a critical drug to treat Black Fungus or Mucormycosis in India12-08-2021
Cadila: More a COVID hedge in the near term
Cadila's India presence -- at about 45 per cent of sales -- is similar in size as the US business and provides better cash-flow visibility12-08-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Unaudited Financial Results for the quarter ended June 202112-08-2021
Cadila Healthcare Ltd - 532321 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Voting results under regulation 44(3) of the Listing Regulations, 2015.11-08-2021
Cadila Healthcare Ltd - 532321 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 26th AGM11-08-2021
Cadila Healthcare Ltd - 532321 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Consolidated results on voting11-08-2021
Earnings Call for Q1FY22 of Cadila Healthcare
Conference Call with Cadila Healthcare Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.11-08-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Update on Investors Presentation11-08-2021